Drug intelligence / Profile preview

KRIYA.748

Development stage: Preclinical
Lead developer: Kriya Therapeutics
Modality: Gene Therapies
Administration: Percutaneous

Overview

KRIYA.748 is an investigational gene therapy being developed by Kriya Therapeutics for the treatment of trigeminal neuralgia. The therapy is designed to deliver DNA directly to target cells, enabling the durable expression of therapeutic proteins following a single administration. This approach aims to provide long-term relief for patients suffering from the chronic and often debilitating facial pain associated with trigeminal neuralgia. KRIYA.748 was part of the pipeline of Terraza Bio, a company focused on neurological gene therapies that was integrated into the Kriya Therapeutics ecosystem.

Targets

PSAM4-GlyR (Engineered varenicline-gated chloride ion channel)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on KRIYA.748.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRIYA.748.

Explore the full profile